Gaotu Techedu Announces Third Quarter 2025 Unaudited Financial Results

Gaotu Techedu Inc. (NYSE: GOTU) (“Gaotu” or the “Company”), a leading technology-driven education company in China focused on enabling lifelong learning through AI-powered solutions, today announced its unaudited financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Highlights[1] — Net revenueswere RMB1,579.0 million, increasedby 30.7% from RMB1,208.3 million in the same […]

CMB.TECH announces Q3 2025 results

(Brussels:CMBT),(NYSE:CMBT), CMB.TECH ANNOUNCES Q3 2025 RESULTSSOFT SUMMER, FOLLOWED BY ROARING TANKER AND DRY BULK MARKETS ANTWERP, Belgium, 26 November 2025 – CMB.TECH NV (“CMBT”, “CMB.TECH” or “the Company”) (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) reported its unaudited financial results today for the third quarter ended 30 September 2025. HIGHLIGHTS Financial highlights:

CMB.TECH announces Q3 2025 results

CMB.TECH announces Q3 2025 results GlobeNewswire November 26, 2025 CMB.TECH ANNOUNCES Q3 2025 RESULTSSOFT SUMMER, FOLLOWED BY ROARING TANKER AND DRY BULK MARKETS ANTWERP, Belgium, 26 November 2025 – CMB.TECH NV (“CMBT”, “CMB.TECH” or “the Company”) (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) reported its unaudited financial results today for the third

Plant Based Proteins and Novel Food Ingredients Market Set to Hit 106 billion Dollars by 2033 as Global Demand Accelerates says, Strategic Revenue Insights (SRI)

Strategic Revenue Insights – The global shift toward healthier and more sustainable food options is reshaping the future of nutrition, and few categories illustrate this transformation as clearly asPlant Based Proteins and Novel Food Ingredients. Consumers, manufacturers, and policymakers are converging on a shared objective that prioritizes health, environmental responsibility, and food security. According to

Kuros Biosciences to present at the Piper Sandler 37th Annual Healthcare Conference

(SWX:KURN), Kuros Biosciences to present at the Piper Sandler 37th Annual Healthcare Conference Schlieren (Zurich), Switzerland, November 26, 2025 – Kuros Biosciences (“Kuros” or the “Company”) a leader in innovative biologic technologies, will present at the Piper Sandler 37th Annual Healthcare Conference, taking place December 2-4, 2025 at The Lotte New York Palace in New

Valneva Announces Positive Final Phase 2 Results for Lyme Disease Vaccine Candidate

(Paris:VLA),(Paris:VLAP), Antibody levels remained well above baseline across all six serotypes and age groups sixth month after third yearly booster dose No safety concerns observed in any age group by an independent Data Monitoring Committee (DMC) Results confirm benefits of a yearly vaccination prior to each Lyme season Saint-Herblain (France), November 26, 2025 – Valneva

Himeji Convention & Visitors Bureau Introduces Special Winter Events in Himeji City, Home to World Heritage Site Himeji Castle

The Himeji Convention & Visitors Bureau will launch an immersive art event at Himeji Castle, a World Cultural Heritage site designated by the Japanese government as a national treasure, starting November 22. It will also introduce three other events taking place in Himeji City during the winter season. Himeji City, located in the southwest of

Renalys Pharma Announces Positive Topline Results from Phase III Study of Sparsentan in Japanese Patients with IgA Nephropathy

In a Phase 3 clinical study evaluating the efficacy and safety of sparsentan in Japanese patients with IgA nephropathy (N=35), the percent change from baseline in the 24-hour urine protein-to-creatinine ratio at Week 36, which was the study's primary endpoint, was -58.54%. Sparsentan was well-tolerated with a profile consistent with other global trials and no

SumiSaujana Announces Solid 18.1% Revenue Growth in Revenue for Q3 FY2025

KUALA LUMPUR, MY / ACCESS Newswire / November 26, 2025 / SumiSaujana Group Berhad ("SumiSaujana" or the "Company") and its subsidiary ("Group"), an established manufacturer of oil and gas ("O&G") specialty chemicals,today announced its unaudited financial results for the third quarter ended 30 September 2025 ("Q3 FY2025"). The Group delivered revenue of RM43.6 million and

Valneva Announces Positive Final Phase 2 Results for Lyme Disease Vaccine Candidate

Valneva Announces Positive Final Phase 2 Results for Lyme Disease Vaccine Candidate GlobeNewswire November 26, 2025 Antibody levels remained well above baseline across all six serotypes and age groups sixth month after third yearly booster dose No safety concerns observed in any age group by an independent Data Monitoring Committee (DMC) Results confirm benefits of

Scroll to Top